Cargando…

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Borderline resectable pancreatic cancer (BRPC) has been primarily indicated for neoadjuvant treatment (NAT) in the last decade. This study is the updated meta-analysis for only patients with BRPC including recent NAT regimens such as FOLFIRINOX. The OS, R0 resection rate, and node-ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hye-Sol, Kim, Hyeong Seok, Kang, Jae Seung, Kang, Yoon Hyung, Sohn, Hee Ju, Byun, Yoonhyeong, Han, Youngmin, Yun, Won-Gun, Cho, Young Jae, Lee, Mirang, Kwon, Wooil, Jang, Jin-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497278/ https://www.ncbi.nlm.nih.gov/pubmed/36139520 http://dx.doi.org/10.3390/cancers14184360

Ejemplares similares

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
por: Choi, Yoo Jin, et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer
por: Lee, Mirang, et al.
Publicado: (2020)

The development and clinical efficacy of simulation training of open duct-to-mucosa pancreaticojejunostomy using pancreas and intestine silicone models
por: Kang, Jae Seung, et al.
Publicado: (2022)

Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreatic ductal adenocarcinoma
por: Lee, Jung Min, et al.
Publicado: (2021)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Comparisons of short-term outcomes of anastomotic methods of duct-to-mucosa pancreaticojejunostomy: out-layer continuous suture versus modified Blumgart method
por: Kang, Yoon Hyung, et al.
Publicado: (2022)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2021)

Predictive Features of Malignancy in Branch Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Meta-Analysis
por: Kwon, Wooil, et al.
Publicado: (2020)

Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy
por: Lee, Mirang, et al.
Publicado: (2023)

Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer
por: Kang, Jae Seung, et al.
Publicado: (2021)

Risk factors deteriorating severe exocrine pancreatic insufficiency measured by stool elastase after pancreatoduodenectomy and the risk factors for weight loss
por: Cho, Ara, et al.
Publicado: (2022)

Clinical characteristics of patients with malignancy and long-term outcomes of surgical treatment of patients with choledochal cyst
por: Han, Wung Sun, et al.
Publicado: (2021)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Clinicoradiological features of resected serous cystic neoplasms according to morphological subtype and preoperative tentative diagnosis: can radiological characteristics distinguish serous cystic neoplasms from other lesions?
por: Kang, Jae Seung, et al.
Publicado: (2020)

Changes in postoperative long-term nutritional status and quality of life after total pancreatectomy
por: Oh, Moon Young, et al.
Publicado: (2021)

Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence
por: Sohn, Hee Ju, et al.
Publicado: (2022)

Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis?
por: Yun, Won-Gun, et al.
Publicado: (2022)

Short- and long-term outcomes of pancreaticoduodenectomy in elderly patients with periampullary cancer
por: Kang, Jae Seung, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

In vivo study for the hemostatic efficacy and foreign body reaction of a new powder-type polysaccharide hemostatic agent
por: Byun, Yoonhyeong, et al.
Publicado: (2022)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

Chronological changes in epidemiologic features of patients with gallstones over the last 20 years in a single large-volume Korean center
por: Zhao, Jiyong, et al.
Publicado: (2019)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Stool Elastase as an Independent Prognostic Factor in Patients with Pancreatic Head Cancer
por: Hwang, Honam, et al.
Publicado: (2022)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Comparison of oncologic outcomes of extrahepatic cholangiocarcinoma according to tumor location: perihilar cholangiocarcinoma versus distal bile duct cancer
por: Lee, Jung Min, et al.
Publicado: (2022)

Oncologic outcomes according to the location and status of resection margin in pancreas head cancer: role of radiation therapy in R1 resection
por: Sohn, Hee Ju, et al.
Publicado: (2022)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

The Optimal Cutoff Value of Tumor Markers for Prognosis Prediction in Ampullary Cancer
por: Lee, Seungho, et al.
Publicado: (2023)

Prognostic Value of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 19-9 (CA 19-9) in Gallbladder Cancer; 65 IU/mL of CA 19-9 Is the New Cut-Off Value for Prognosis
por: Kim, Myongjin, et al.
Publicado: (2021)

Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
por: Damm, Marko, et al.
Publicado: (2021)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Clinical meaning of the World Health Organization morphologic classification (flat vs. tumoral) of gallbladder intraepithelial neoplasm as a prognostic factor in gallbladder cancer
por: Kim, Hongbeom, et al.
Publicado: (2020)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
por: Doppenberg, Deesje, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series
por: Gorbudhun, Rachna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sb60lk0l8oiubdmkd18ej11ks